Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.

about

A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use

P2860

Q36595921-A2BF6F02-1903-4D30-93DD-DEE07EA299F2

P2860

Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.

Item

http://www.wikidata.org/entity/Q43921722

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Serum free light chain reducti ...... d/refractory multiple myeloma.

@en

Serum free light chain reducti ...... d/refractory multiple myeloma.

@nl

type

Item

label

Serum free light chain reducti ...... d/refractory multiple myeloma.

@en

Serum free light chain reducti ...... d/refractory multiple myeloma.

@nl

prefLabel

Serum free light chain reducti ...... d/refractory multiple myeloma.

@en

Serum free light chain reducti ...... d/refractory multiple myeloma.

@nl

P1476

Serum free light chain reducti ...... d/refractory multiple myeloma.

@en

P2093

Andrzej J Jakubowiak

http://www.w3.org/2001/XMLSchema#string

David S Siegel

http://www.w3.org/2001/XMLSchema#string

Edward Kavalerchik

http://www.w3.org/2001/XMLSchema#string

Mei Huang

http://www.w3.org/2001/XMLSchema#string

Michael Wang

http://www.w3.org/2001/XMLSchema#string

Ravi Vij

http://www.w3.org/2001/XMLSchema#string

Sundar Jagannath

http://www.w3.org/2001/XMLSchema#string

P2860

Appraisal of immunoglobulin free light chain as a marker of response

Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.

International uniform response criteria for multiple myeloma.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Association of response endpoints with survival outcomes in multiple myeloma.

P304

2959-2961

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2015.1020801

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ruben Niesvizky

P577

2015-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25699653

http://www.w3.org/2001/XMLSchema#string

Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.

about

P2860

P2860

Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698